MSF urges South Africa to nix AbbVie patent on shortage-plagued HIV med; GSK touts Shingrix, Advair studies;

@FiercePharma: Roche's O'Day says portfolio firing well in international markets, Japan a star. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: "I've heard two CEOs use the word 'bold' in the last couple months..." - DB's Gilbert insinuating a $PFE $AGN tie-up. | Follow @CarlyHFierce

> Doctors Without Borders/Médecins Sans Frontières is calling on the South African government to override AbbVie's ($ABBV) patent on an HIV drug, Aluvia, that has been in short supply for 6 months. Release

> GlaxoSmithKline ($GSK) said its shingles vaccine, Shingrix, demonstrated 90% efficacy in adults 70 years and over, compared with placebo. Release

> GSK said a long-term safety study of its combination lung drug Advair showed that it had a safety profile comparable with fluticasone propionate--one of its two active ingredients--in adolescents and adults with asthma. Release

> Mylan ($MYL) rolled out its generic version of Spectrum Pharmaceuticals' ($SPPI injectable therapy Fusilev (levoleucovorin calcium), which had U.S. sales of about $200 million over the 12 months ended June 30. Release

Medical Device News

@FierceMedDev: ICYMI: Healthcare, wellness drive Philips growth as it works to shed lighting. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: J&J device heads say the new med tech innovation model calls for more external partnerships. Article | Follow @VarunSaxena2

@EmilyWFierce: Stanford scientists reveal artificial skin device for prosthetics. Story | Follow @EmilyWFierce

> Endologix off more than 25% on planned $211M merger with TriVascular. More

> NEA, Cleveland Clinic, Greatbatch back $20M Series A for neuromodulation heart failure startup. Story

Biotech News

@FierceBiotech: GlaxoSmithKline's cardio R&D group records another big PhIII flop. News | Follow @FierceBiotech

@JohnCFierce: Kite Pharma taps Mitch Gold's upstart Alpine for T-cell immuno-tech. Article | Follow @JohnCFierce

> After a big-money Allergan deal, Taris returns with a $32M round and a new pipeline. Item

> After Eli Lilly flop, Merck adds a futility challenge to huge PhIII anacetrapib study. Article

Pharma Manufacturing News

> U.K. cites the GSK China plant that was damaged by explosions. News

> Sun recalls 1M-plus boxes of generic Claritin made at Ohm Labs. Report

> Boehringer's Roxane plant mixes up APIs for blood pressure med. Story

> Lawsuit challenges Cipla's buyout of InvaGen. Item

> Spain's Grifols opening $100M warehouse, labeling operation in Dublin. Article

Drug Delivery News

> MIT: Ultrasound gives GI drugs a quicker delivery with less discomfort. Story

> 'Screen door' through blood-brain barrier gives Parkinson's drugs a way in. More

> Capsugel launches coating-free enteric protection delivery platform for oral meds. News

> FDA approval of Endo and BDSI's painkiller a win for buccal drug delivery. Item

> Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Report

Pharma Asia News

> Tata Institute says paper shows 'early success' in malaria vaccine. More

> Indian health officials slam Lancet editor's comments. Article

> Lilly takes Q3 hits in emerging markets on FX, but Japan shows bright spots. Story

> Roche's O'Day says portfolio firing well in international markets, Japan a star. More

> China's ZAI Lab goes novel in drug development, makes key hire. Report

And Finally... Investment banks may be worried now that Valeant Pharmaceuticals ($VRX) says it will be more selective about M&A; the specialty drugmaker has accounted for a big chunk of investment-banker fees over the past three years. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.